SCHEMBL1747925

SCHEMBL1747925

Cc1cccc2sc(Cl)nc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.61
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
KDM4E B2RXH2 2/20 0.48
HPGD P15428 2/20 0.48
MAPT P10636 5/20 0.47
PKM P14618 1/20 0.45
POLB P06746 2/20 0.44
ALOX15 P16050 2/20 0.44
USP2 O75604 1/20 0.44
MCL1 Q07820 1/20 0.44
ESR2 Q92731 1/20 0.44
HSD17B10 Q99714 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
GAA P10253 2/20 0.44
LMNA P02545 3/20 0.43
PDE10A Q9Y233 1/20 0.43
AGPAT2 O15120 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14127131 1.00 ALDH1A1 (0.61) ALDH1A1MEN1KMT2AKDM4EHPGD
SCHEMBL1747928 0.79 LMNA (0.66) ALDH1A1MEN1KMT2AKDM4EHPGD
SCHEMBL1748098 0.79 ALDH1A1 (0.66) ALDH1A1MEN1KMT2AKDM4EHPGD
SCHEMBL14127197 0.78 ALDH1A1 (0.63) ALDH1A1MEN1KMT2AKDM4EHPGD
SCHEMBL3918916 0.78 ALDH1A1 (0.63) ALDH1A1MEN1KMT2AKDM4EHPGD
Iodide SCHEMBL1770191 0.78 ALDH1A1 (0.63) ALDH1A1MEN1KMT2AKDM4EHPGD
SCHEMBL3790319 0.78 ALDH1A1 (0.58) ALDH1A1MEN1KMT2AKDM4EHPGD
SCHEMBL28471609 0.77 ALDH1A1 (0.49) ALDH1A1MEN1KMT2AKDM4EHPGD
SCHEMBL30066905 0.76 ALDH1A1 (0.56) ALDH1A1MEN1KMT2AKDM4EHPGD
SCHEMBL4338958 0.76 ALDH1A1 (0.56) ALDH1A1MEN1KMT2AKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113045993-A Polishing solution for processing ultra-smooth low-damage bearing steel surface and application thereof 西南交通大学 2021-06-29 CN claimed
CN-104419326-A Slurry composition for chemical mechanical polishing COWON INNOTECH INC 2015-03-18 CN claimed
CN-113045993-A Polishing solution for processing ultra-smooth low-damage bearing steel surface and application thereof 西南交通大学 2021-06-29 CN disclosed
CN-109054648-A Serosity combination for chemically mechanical polishing LTCAM有限公司 2018-12-21 CN disclosed
US-9156834-B2 Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy PIERRE FABRE MEDICAMENT (FR) 2015-10-13 US disclosed
US-9156834-B2 Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy PIERRE FABRE MEDICAMENT (FR) 2015-10-13 US disclosed
US-9156834-B2 Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy PIERRE FABRE MEDICAMENT (FR) 2015-10-13 US disclosed
CN-103209980-B Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy PF MEDICAMENT 2015-06-03 CN disclosed
CN-104419326-A Slurry composition for chemical mechanical polishing COWON INNOTECH INC 2015-03-18 CN disclosed
US-20140357624-A1 DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY PF MEDICAMENT (FR) 2014-12-04 US disclosed
US-20140357624-A1 DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY PF MEDICAMENT (FR) 2014-12-04 US disclosed
US-5629007-A USING BENZOQUINOLIN-3-ONE DERIVATIVES ELI LILLY AND COMPANY (US) 1997-05-13 US disclosed
US-5622961-A PROSTATE CANCER, SKIN DISORDERS, BALDNESS ELI LILLY AND COMPANY (US) 1997-04-22 US disclosed
US-5622962-A PROSTATE CANCER, SKIN DISORDERS, BALDNESS ELI LILLY AND COMPANY (US) 1997-04-22 US disclosed
CN-1138458-A Treatment and prevention of prostatic cancer LILLY CO ELI (US) 1996-12-25 CN disclosed
US-5578724-A INHIBITORS OF 5-ALPHA-REDUCTASE ELI LILLY AND COMPANY (US) 1996-11-26 US disclosed
WO-1996035422-A1 METHODS FOR INHIBITING BONE LOSS ELI LILLY AND COMPANY (US) 1996-11-14 WO disclosed
EP-0742010-A2 Benzoquinolin-3-ones to inhibit bone loss ELI LILLY AND COMPANY (US) 1996-11-13 EP disclosed
EP-0733365-A2 Use of benzoquinolin-3-ones for the treatment and prevention of prostatic cancer ELI LILLY AND COMPANY (US) 1996-09-25 EP disclosed
US-5550134-A ADMINISTERING TO A MAMMAL FROM A SERIES OF BENZOQUINOLIN-3-ONE COMPOUNDS ELI LILLY AND COMPANY (US) 1996-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140357624-A1 DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY KCNA4, KCNA1, KCNB1 ALDH1A1 2839/4885MEN1 844/4885KMT2A 1058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.